Showing 2711-2720 of 3318 results for "".
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Analysis Concludes No Single Preclinical Model Fully Mimics Human PsOhttps://practicaldermatology.com/news/Analysis-Concludes-No-Single-Preclinical-Model-Fully-Mimics-Human-PsO/2475576/Despite extensive preclinical model development, no single system fully mimics human psoriatic disease, according to a new analysis published in Expert Opinion on Drug Discovery. Researchers on the study emphasized the importance of preclinical models that can reproduce disease-re
- Study: Iron Oxide Formulation Improved Radiance in Melasma-Prone Skinhttps://practicaldermatology.com/news/study-feo-formulation-improves-radiance-in-melasma-prone-skin/2475517/A new study published in Journal of Drugs in Dermatology evaluated the incorporation of iron oxide (FeO) into a daily sun care routine could offer protection and any benefit for patients with melasma and photodamage.
- SKINVIVE sPMA Accepted for Neck Line Treatmenthttps://practicaldermatology.com/news/skinvive-spma-accepted-for-neck-line-treatment/2475452/The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental premarket approval (sPMA) application from Allergan Aesthetics, an AbbVie company, for SKINVIVE by JUVÉDERM® for the treatment of neck lines in adults, according to a press release.<
- Study: Cost of AD Care Higher in Low-Income Areashttps://practicaldermatology.com/news/study-cost-of-ad-care-higher-in-low-income-areas/2475282/Recommended skin care products for atopic dermatitis (AD) were found to be more expensive and less accessible in lower-income neighborhoods, new research in the Journal of Drugs in Dermatology indicates. "Pharmacy des
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://practicaldermatology.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://practicaldermatology.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2474873/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics. Citing more than thre
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.